ArticlePharmacoEconomics2024

Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.

Takao Takeshima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.